Patients with refractory non-Hodgkin lymphoma showed high rates of objective responses when treated with an investigational autologous cell therapy, Reuters reported on the basis of topline results released by the product's manufacturer.
The so-called CAR T-cell therapy involves ex vivo manipulation of patients' own T cells to induce production of antibodies that enable them to hunt down and kill lymphoma cells.
In a trial called ZUMA-1, patients with either diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma showed 6-month objective response rates of 43% and complete response rates of 36%, said manufacturer Kite Pharma of Santa Monica, Calif.
Reuters noted that several other firms are also developing CAR T-cell therapies. Analysts told the news service that, on the strength of the ZUMA-1 results, Kite Pharma could win an accelerated approval for its product by the end of this year.
This article was published first by MedPageToday Immunotherapy 'Highly Effective' in Lymphoma Trial (Reuters), a trusted and reliable source for clinical and policy coverage, and free Continuing Medical Education (CME), that directly affects the lives and practices of health care professionals.